Methods for determining isolated p27 protein levels and uses thereof
First Claim
Patent Images
1. A method for determining the relative amount of p27 protein in a cell or sample of cells (cell sample) comprising (i) determining the level of a p27 protein having a sequence of one of SEQ ID Nos. 2, 4, and 6 in the cell sample, and (ii) comparing the level of the p27 protein in the cell sample with the level of a wild-type p27 protein determined for a control cell, wherein the wild-type p27 protein inhibits activation of a cyclin E-Cdk2 (cyclin-dependent kinase-2) complex and has an amino acid sequence of one of SEQ ID Nos. 2, 4, and 6.
6 Assignments
0 Petitions
Accused Products
Abstract
The subject invention is directed to the discovery of a protein involved in regulation of cell-cycle progression, and includes reagents and methods related thereto.
-
Citations
13 Claims
- 1. A method for determining the relative amount of p27 protein in a cell or sample of cells (cell sample) comprising (i) determining the level of a p27 protein having a sequence of one of SEQ ID Nos. 2, 4, and 6 in the cell sample, and (ii) comparing the level of the p27 protein in the cell sample with the level of a wild-type p27 protein determined for a control cell, wherein the wild-type p27 protein inhibits activation of a cyclin E-Cdk2 (cyclin-dependent kinase-2) complex and has an amino acid sequence of one of SEQ ID Nos. 2, 4, and 6.
-
2. A method for diagnosing a hyperproliferative disorder characterized by abnormal cell proliferation in a patient, comprising:
- (i) ascertaining the level of a p27 protein having an amino acid sequence of one of SEQ ID Nos. 2, 4, and 6 in a sample of cells from the patient; and
(ii) diagnosing the presence or absence of a hyperproliferative disorder including utilizing the ascertained level of the p27 protein, wherein a reduced level of the p27 protein in the sample, relative to a level of a wild-type p27 protein in a control sample of normal cells, correlates with the presence of a hyperproliferative disorder, and the wild-type p27 protein inhibits activation of a cyclin E-Cdk2 (cyclin-dependent kinase) complex and has an amino acid sequence of one of SEQ ID Nos. 2, 4, and 6. - View Dependent Claims (6, 7)
- (i) ascertaining the level of a p27 protein having an amino acid sequence of one of SEQ ID Nos. 2, 4, and 6 in a sample of cells from the patient; and
-
3. A method for evaluating a cancer patient'"'"'s prognosis, comprising (i) ascertaining the level of a p27 protein having an amino acid sequence of one of SEO ID Nos. 2, 4, and 6 in a sample of cancer cells from the patient;
- and (ii) comparing the ascertained level of the p27 protein to a level of wild-type p27 protein in a normal control sample of cells, wherein a reduced level of the p27 protein in the sample correlates with an increased risk of recurrence of a cancer, and wherein the wild-type p27 protein inhibits activation of a cyclin E-Cdk2 (cyclin-dependent kinase-2) complex and has an amino acid sequence of one of SEQ ID Nos. 2, 4, and 6.
- View Dependent Claims (8, 9, 10, 11, 12, 13)
-
4. A method for determining the relative amount of p27 protein in a cell or sample of transformed cells (cell sample) from a patient comprising (i) determining the level of p27 protein having an amino acid sequence of one of SEQ ID Nos. 2, 4, and 6 in the cell sample, and (ii) comparing the level of p27 protein in the cell sample with the level of p27 protein determined for a control cell, wherein the p27 protein inhibits activation of a cyclin E-Cdk2 (cyclin-dependent kinase) complex and has an amino acid sequence of one of SEQ ID Nos. 2, 4, and 6.
Specification